New and emerging therapies for Melanoma

Authors

Sonia Amin Thomas, Philadelphia College of Osteopathic MedicineFollow
A. G. Douglas
A. Rose
E. Dingsangha
Valerie Tapia

Document Type

Article

Publication Date

2015

Abstract

Melanoma is a leading cause of skin cancer mortality in the United States. Treatment for melanoma had been limited to very few agents, including chemotherapy, with older treatment options such as interferon and interleukin-2 causing toxic adverse effects. Since the approval of the monoclonal antibody ipilimumab in 2011, there have been several new drugs approved for metastatic melanoma. Recently, there have been approvals of kinase inhibitors and programmed death receptor-1 (PD-1) inhibitors for unresectable or metastatic melanoma, including vemurafenib, nivolumab, and pembrolizumab. These agents have been considered breakthrough therapies in the treatment of melanoma.

Publication Title

U.S. Pharmacist

Volume

40

Issue

11

First Page

3

Last Page

6

Comments

This article was published in U.S. Pharmacist, Volume 40, Issue 11, Pages 3-6.

The published version is available at http://www.uspharmacist.com/supplements/s/394/.

Copyright © 2015 Jobson Medical Publishing.

Recommended Citation

Thomas, Sonia Amin; Douglas, A. G.; Rose, A.; Dingsangha, E.; and Tapia, Valerie, "New and emerging therapies for Melanoma" (2015). PCOM Scholarly Papers. 1658.
https://digitalcommons.pcom.edu/scholarly_papers/1658